NEUROPACE, INC.

Insiders NeuroPace, Inc.

Equities

NPCE

US6412881053

Real-time Estimate Cboe BZX Other stock markets 10:14:23 2024-05-21 am EDT			5-day change	1st Jan Change
7.9 ^USD	-1.00%		-7.17%	-23.38%

May. 13	Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating	MT
May. 08	NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary	Feb. 07	CI
NeuroPace Appoints Joel Becker as Chief Executive	23-06-28	MT
Neuropace, Inc. Announces Board Member Changes	23-06-28	CI
Neuropace, Inc. Announces Chief Executive Officer Changes	23-06-28	CI
NeuroPace, Inc. Announces Resignation of Greg Garfield as Director	23-04-13	CI
NeuroPace, Inc. Appoints Dr. Uri Geiger to Board of Directors	23-01-09	CI
Neuropace, Inc. Announces Addition of Lisa Andrade to the Board	21-10-19	CI
NeuroPace, Inc. Names Mark Saxton as Vice President of Sales	19-07-31	CI
NeuroPace, Inc. Announces Management Changes	19-07-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW